SRPT - CIK 0000873303
Sarepta Therapeutics, Inc. trades as SRPT and has a market capitalization of $1.88 B, making it the #2138 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.86B, down 2.0% from the prior year and net income of -$713.41M. This page tracks Sarepta Therapeutics, Inc. through 1,504 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Sarepta Therapeutics, Inc.'s revenue grew from $5.42M to $1.86B, a compound annual growth rate of 91.3%. Net profit margin expanded from -4930.2% to -38.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Institutional holdings | 13F-HR | 2026-05-13 |
| Major company event | 8-K | 2026-05-06 |
| Quarterly report | 10-Q | 2026-05-06 |
| SCHEDULE 13G | - | 2026-04-30 |
| SCHEDULE 13G | - | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-24 |
| Proxy materials | DEFA14A | 2026-04-24 |
| Proxy statement | DEF 14A | 2026-04-24 |
Sarepta Therapeutics to Participate in Upcoming Investor Conferences | Sarepta Therapeutics, Inc.
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program | Sarepta Therapeutics, Inc.
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference | Sarepta Therapeutics, Inc.
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments | Sarepta Therapeutics, Inc.
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results | Sarepta Therapeutics, Inc.
The largest companies sharing Sarepta Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Sarepta Therapeutics, Inc. (SRPT) has a market capitalization of $1.88 B as of 2026-05-29, ranking #2138 among US-listed companies.
Sarepta Therapeutics, Inc. reported revenue of $1.86B for fiscal year 2025, a decrease of 2.0% year over year.
In its latest fiscal year Sarepta Therapeutics, Inc. reported a net loss of $713.41M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.